1. Home
  2. WNEB vs IMRX Comparison

WNEB vs IMRX Comparison

Compare WNEB & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western New England Bancorp Inc.

WNEB

Western New England Bancorp Inc.

HOLD

Current Price

$13.81

Market Cap

264.8M

Sector

Finance

ML Signal

HOLD

IMRX

Immuneering Corporation

HOLD

Current Price

$5.04

Market Cap

288.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WNEB
IMRX
Founded
1853
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
264.8M
288.6M
IPO Year
2001
2021

Fundamental Metrics

Financial Performance
Metric
WNEB
IMRX
Price
$13.81
$5.04
Analyst Decision
Buy
Strong Buy
Analyst Count
3
5
Target Price
$13.67
$17.20
AVG Volume (30 Days)
49.6K
602.4K
Earning Date
04-28-2026
05-04-2026
Dividend Yield
2.00%
N/A
EPS Growth
33.93
37.75
EPS
0.42
N/A
Revenue
$44,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$7.25
N/A
P/E Ratio
$32.62
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.78
$3.86
52 Week High
$15.01
$10.08

Technical Indicators

Market Signals
Indicator
WNEB
IMRX
Relative Strength Index (RSI) 47.32 56.89
Support Level $13.28 $4.82
Resistance Level $13.96 $5.38
Average True Range (ATR) 0.25 0.22
MACD -0.00 0.02
Stochastic Oscillator 38.85 68.18

Price Performance

Historical Comparison
WNEB
IMRX

About WNEB Western New England Bancorp Inc.

Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the company's revenues, profits, and assets are derived by the Bank from banking products and services.

About IMRX Immuneering Corporation

Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.

Share on Social Networks: